{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '7', 'STATISTICAL METHODOLOGY', 'A Statistical Analysis Plan (SAP) will be written to provide details of the analysis, along with', 'specifications for tables, listings and figures to be produced. The SAP will be finalized before', 'the first subject is enrolled. Any changes from the analyses planned in SAP will be justified', 'in the Clinical Study Report.', 'In general, continuous data will be summarized with descriptive statistics (number of subjects,', 'mean, SD, minimum, median and maximum), and frequency and percentage for categorical data.', '7.1', 'Sample Size', 'Approximately 600 subjects will be randomized in a 1:1 ratio to 2 treatment arms: EV', '(Arm A) and chemotherapy (Arm B). Randomization will be stratified by baseline ECOG PS', '(0 VS 1), regions of the world (Western EU, US or the rest of world) and liver metastasis (yes', 'or no). Assuming HR = 0.75 (median OS in Arm A and Arm B are 10.7 months and', '8 months, respectively) drop-out rate of 10%, the final analysis at the planned 439 death', 'events and 1 interim analysis at 65% of the total planned events (285 death events), this', 'sample size will provide 85% power to detect a statistically significant difference at overall', 'type I error rate of 1-sided 0.025.', 'Sample size is determined by primary endpoint OS; the 600 subjects will provide more than', '90% power to detect statistically significant differences on selected secondary endpoints:', 'PFS1 (assuming median PFS1 in Arm A and Arm B are 6 months and 4 months,', 'respectively), ORR and DCR (assuming 15% treatment difference between Arm A and Arm', 'B for both ORR and DCR).', '7.2', 'Analysis Sets', 'Detailed criteria for analysis sets will be laid out in SAP or Classification Specifications and', 'the allocation of subjects to analysis sets will be determined prior to database hard-lock.', '7.2.1', 'Full Analysis Set', 'The full analysis set (FAS) will consist of all subjects who are randomized. This analysis set', 'is in compliance with the intent to treat (ITT) principle that includes all randomized subjects,', 'the FAS is equivalent to the ITT population. This will be the primary analysis set for efficacy', 'analyses except for response related efficacy endpoints.', '7.2.2', 'Safety Analysis Set', 'The safety analysis set (SAF), which consists of all subjects who received any amount of', 'study drug, will be used for safety analyses.', '7.2.3', 'Response Evaluable Set', 'The response evaluable set (RES) is defined as all subjects in FAS and with measurable', 'disease (per RECIST V1.1) at baseline. RES will be used for primary efficacy analysis of', 'response related endpoints, e.g., ORR and DCR.', '14 Sep 2020', 'Astellas', 'Page 85 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '7.2.4', 'Pharmacokinetic Analysis Set', 'Pharmacokinetics Analysis Set (PKAS) includes subjects who received active drug for whom', 'at least one blood sample was collected and assayed for measurement of the TAb, ADC and', 'MMAE serum/plasma concentrations and for whom the time of sampling and the time of', 'dosing on the day of sampling is known.', '7.3', 'Demographics and Baseline Characteristics', 'Demographics and baseline characteristics will be summarized by treatment group and', 'overall. Ethnic origin will only be summarized in demographic table. Descriptive statistics', 'will include number of subjects, mean, standard deviation, minimum, median and maximum', 'for continuous endpoints, and frequency and percentage for categorical endpoints.', '7.3.1', 'Subject Disposition', 'The number and percentage of subjects who completed and discontinued treatment and', 'reasons for treatment discontinuation will be presented for all randomized subjects and for', 'subjects in the SAF by treatment group and overall. Similar tables for screening disposition,', 'investigational period disposition and follow-up disposition will also be presented for all', 'randomized subjects by treatment group and overall. All disposition details and dates of first', 'and last evaluations for each subject will be listed.', '7.3.2', 'Previous and Concomitant Medications', 'All previous and concomitant medications will be presented in a listing. The frequency of', 'concomitant medications (prescription, over-the-counter and nutritional supplements) will be', 'summarized by treatment group and preferred term (PT) for SAF. Medications will be coded', 'using the WHO drug dictionary. Medications will be counted by the number of subjects who', 'took each medication. A subject taking the same medication multiple times will only be', 'counted once for that medication. Medications will be presented in decreasing order of', 'frequency based on the total number of subjects who took each medication.', '7.3.3', 'Medical History', 'Medical history for each subject will be presented in a listing. A detailed medical history for', 'each subject will be obtained during screening period and will be summarized by treatment', 'group and overall.', '7.4', 'Analysis of Efficacy', 'Efficacy analysis for OS and PFS will be conducted on the FAS. The interpretation of results', 'from statistical tests will be based on the FAS. Efficacy analysis for response related', 'endpoints, e.g., ORR and DCR will be conducted on RES.', 'The family-wise type I error rate for this study is strongly controlled at 2.5% (one-sided) that', 'allows the study to declare positive on primary endpoint os on the FAS population. OS will', 'be formally tested at both interim analysis and final analysis. Formal hypothesis tests on the', 'selected secondary endpoints including PFS1, ORR and DCR, will be performed', 'hierarchically (per the order of PFS1-> ORR->DCR) only when the OS analysis is rejected.', '14 Sep 2020', 'Astellas', 'Page 86 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}